Pluri Inc.
PLUR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PLUR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLUR
Pluri Inc. is a biotechnology company leveraging its proprietary cell expansion platform to develop scalable, cell-based solutions across healthcare, food, and agriculture sectors, with a current focus on regenerative medicine and a Phase I study for knee osteoarthritis.
Key risk: Negative equity and cash burn
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 1 pipeline candidate for Pluri Inc..
Pluri Inc. is a biotechnology company leveraging its proprietary cell expansion platform to develop scalable, cell-based solutions across healthcare, food, and agriculture sectors, with a current focus on regenerative medicine and a Phase I study for knee osteoarthritis.
- Pluri Inc. is a biotechnology company leveraging a proprietary cell expansion platform for regenerative medicine, immunotherapy, food technology, and agriculture [sec_mda · as of 2026-02-12].
- The company is conducting a Phase I study of PLX-PAD for mild to moderate knee osteoarthritis under an agreement with Charité, led by Professor Tobias Winkler [sec_mda · as of 2026-02-12].
- As of 2026-03-31, Pluri reported cash & equivalents of $4.6M, total revenue of $0.2M, net income of -$5.5M, and shareholders' equity of -$6.8M [sec].
- The company is addressing liquidity issues through a cost-reduction plan and initiatives to obtain additional capital, licensing partnerships, CDMO services, and other funding [sec_mda · as of 2026-02-12].
What works
- Pluri's proprietary cell expansion platform is versatile, targeting multiple sectors (regenerative medicine, immunotherapy, food tech, agriculture), which may diversify revenue streams [sec_mda · as of 2026-02-12].
- The company has initiated a Phase I clinical study for PLX-PAD in knee osteoarthritis with a reputable academic partner (Charité), indicating progress in its lead therapeutic program [sec_mda · as of 2026-02-12].
What to weigh
- Pluri has negative shareholders' equity of -$6.8M as of 2026-03-31, indicating a weak balance sheet [sec].
- The company's cash position of $4.6M as of 2026-03-31 is low relative to its net loss of $5.5M for the same period, suggesting a limited cash runway [sec].
- Pluri's ability to continue operations depends on securing additional capital, licensing partnerships, or other funding, with no assurance of success [sec_mda · as of 2026-02-12].
- Near-term revenues are unlikely to exceed operating costs, and the company faces risks in clinical trial execution and regulatory approval [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
Pluri's platform targets multiple sectors including regenerative medicine, immunotherapy, and food technology.
“the expected development, time-to-market and potential benefits from our products and ventures, based on our cell-based technology platform in regenerative medicine, immunotherapy, food technology”
SEC MD&A · February 12, 2026
Pluri has an agreement with Charité for a Phase I study of PLX-PAD in knee osteoarthritis.
“In November 2025, the Company entered into an agreement with Charité governing the execution of the Phase I study of PLX-PAD for the treatment of mild to moderate knee osteoarthritis”
SEC MD&A · February 12, 2026
Pluri is addressing liquidity issues through a cost-reduction plan and seeking additional capital.
“We are addressing our liquidity issues by implementing initiatives to allow the continuation of our activities. Our current operating plan includes various assumptions concerning the level and timing of cash outflows for operating activities and capital expenditures, which include a cost-reduction plan.”
SEC MD&A · February 12, 2026
Risks & what to watch (4)›
Key risks
- Negative equity and cash burn — Shareholders' equity of -$6.8M and net loss of $5.5M as of 2026-03-31 indicate severe financial strain [sec].
- Dependence on external funding — Pluri's business plan depends on obtaining additional capital, partnerships, or grants, with no assurance of success [sec_mda · as of 2026-02-12].
- Clinical and regulatory uncertainty — Products may not be approved by regulatory agencies, and clinical trials may face delays or obstacles [sec · filed 2026-06-22].
- Low near-term revenue — Near-term revenues are unlikely to exceed operating costs, limiting internal funding [sec_mda · as of 2025-11-12].
What to watch
- Progress and results of the Phase I study of PLX-PAD for knee osteoarthritis, including any updates from Charité [sec_mda · as of 2026-02-12].
- Pluri's ability to secure additional capital, licensing partnerships, or CDMO contracts to extend its cash runway [sec_mda · as of 2026-02-12].
- Any restructuring or outcome of the EIB loan negotiations, as referenced in the liquidity plan [sec_mda · as of 2026-02-12].
- Updates on the company's cost-reduction plan and its impact on cash burn rate [sec_mda · as of 2026-02-12].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Pluri Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pluri Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
4.2 months
OCF -$5M · Net income -$6M
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$105K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 19,424 | $66K |
| eversource wealth advisors, llc | 2,270 | $21K |
| morgan stanley | 3,076 | $10K |
| citigroup inc | 1,360 | $5K |
| sima wealth partners, llc | 350 | $1K |
| wells fargo & company/mn | 185 | $628 |
| td waterhouse canada inc. | 93 | $312 |
| osaic holdings, inc. | 50 | $170 |
| winch advisory services, llc | 26 | $88 |
| tfc financial management, inc. | 19 | $65 |
Showing top 10 of 11 institutional holders of Pluri Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.0%
- Days to cover
- 4.3
- Shares short
- 20,487
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLUR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pluri Inc.?
Pluri Inc. is a biotechnology company leveraging its proprietary cell expansion platform to develop scalable, cell-based solutions across healthcare, food, and agriculture sectors, with a current focus on regenerative medicine and a Phase I study for knee osteoarthritis.
What is Pluri Inc.'s lead drug candidate?
Pluri Inc.'s most advanced tracked candidate is plx-r18 (Phase 1) for Incomplete recovery following hematopoietic cell transplantation (HCT) and Hematopoietic Acute Radiation Syndrome (H-ARS).
Who is the CEO of Pluri Inc.?
Mr. Yaacov Yanay is the chief executive officer of Pluri Inc. (PLUR).
Where is Pluri Inc. headquartered?
Pluri Inc. (PLUR) is headquartered in Haifa, Israel.
What therapeutic areas does Pluri Inc. focus on?
Pluri Inc. develops therapies across Oncology, Immunology, Cardiovascular, Respiratory, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.